Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) has provided an update.
Radiopharm Theranostics announced its participation in the Leerink Partners Global Healthcare Conference 2025 in Miami and the NWR Virtual Healthcare Conference. The company’s Chief Medical Officer, Dr. Dimitris Voliotis, is engaging with investors and presenting at these events, reflecting Radiopharm’s active role in the healthcare industry and its commitment to advancing its radiopharmaceutical platform. This engagement is likely to enhance the company’s visibility and strengthen its position in the market.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited is a clinical stage radiotherapeutics company focused on developing innovative radiopharmaceutical products for diagnostic and therapeutic applications, particularly in areas with high unmet medical needs. The company, listed on the ASX since November 2021, boasts a robust pipeline of differentiated molecules, including peptides, small molecules, and monoclonal antibodies, aimed at treating various cancers such as brain, lung, breast, and pancreas.
YTD Price Performance: 20.04%
Average Trading Volume: 224,232
Current Market Cap: $45.75M
See more insights into RADX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com